Takeda Emphasizes Strategy for Delivering Sustainable Growth

− On Track for Continued Topline Growth With Potential to Deliver Incremental Revenue by FY20251 Driven by its 14 Global Brands− Highly Diversified Pipeline of Approximately 40 Potential Therapies Expected to Drive Growth Beyond FY2025− Delivering on Financial Commitments, Including Strong Underlying Core Operating...

Related Keywords

Japan , China , Osaka , United States , Japanese , Christophe Weber , Christina Beckerman , Adaptate Biotherapeutics , Ryoko Matsumoto , Exchange Commission , International Financial Reporting Standards , Takeda Pharmaceutical Company Limited , International Media , Takeda Pharmaceutical Company , Continued Topline Growth With Potential , Deliver Incremental Revenue , Highly Diversified Pipeline , Therapies Expected , Drive Growth Beyond , Financial Commitments , Strong Cash Flow , Healthcare Conference , Chief Executive Officer , Term Growth Expected , Deliver Sustained , Pharmaceutical Company Limited , Rare Genetics , Plasma Derived Therapies , Annual Report , Underlying Revenue , Core Operating Profit , Underlying Core Operating Profit , Core Net Profit , Underlying Core , Net Debt , Free Cash , Regulatory Success ,